Silver Book Fact

Pioglitazone associated with relative risk reduction in recurrent stroke

The PROactive trial to manage glucose in diabetics with a history of cardiovascular disease, stroke, or other vascular risk factors found that treatment with pioglitazone was associated with a 47% relative risk reduction in recurrent stroke.

Wilcox R, Bousser M, Betteridge J, Scernthaner G, et al. Effects of Pioglitazone in Patients with Type 2 Diabetes with or without Previous Stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial in macro Vascular Events 04). Stroke. 2007; 38(3): 865-73. http://stroke.ahajournals.org/cgi/content/short/38/3/865

Reference

Title
Effects of Pioglitazone in Patients with Type 2 Diabetes with or without Previous Stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial in macro Vascular Events 04)
Publication
Stroke
Publication Date
2007
Authors
Wilcox R, Bousser M, Betteridge J, Scernthaner G, et al
Volume & Issue
Volume 38, Issue 3
Pages
865-73
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Increased use of a blood-thinning drug prevents 40,000 strokes every year in the U.S.  
  • It is estimated that the number of quality-adjusted life-years achieved with each $1 million spent on antihypertensive drug therapy is between 20-50 to more than 200.  
  • The use of ACE inhibitors in hypertensive patients 80 years of older was associated in this study with a 30% reduction in the rate of stroke and a 64% reduction…  
  • Satisfaction with HVD Treatment
    Among treated heart valve disease (HVD), 96% express “full satisfaction” and 78% are “very satisfied” with their treatment.  
  • Because of the advent of imaging and noninvasive testing, Americans who are asymptomatic are being diagnosed with established cardiovascular disease.